MODEL

Serial Number 98106330
730

Registration Progress

Application Filed
Jul 28, 2023
Under Examination
Nov 5, 2024
Approved for Publication
Sep 10, 2024
Published for Opposition
Sep 10, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 1 Granted
Due: Nov 05, 2025 99 days

Trademark Image

MODEL

Basic Information

Serial Number
98106330
Filing Date
July 28, 2023
Published for Opposition
September 10, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Apr 21, 2025
Application
Pending
Classes
005 042

Rights Holder

Aliada Therapeutics, Inc.

03
Address
200 Berkeley St, 18th floor
Boston, MA 02116

Ownership History

Aliada Therapeutics, Inc.

Original Applicant
03
Boston, MA

Aliada Therapeutics, Inc.

Owner at Publication
03
Boston, MA

Legal Representation

Attorney
Cheryl A. Withycombe

USPTO Deadlines

Next Deadline
99 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
November 05, 2025
Extension Available
Until November 05, 2025

Application History

30 events
Date Code Type Description Documents
Apr 22, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 21, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 21, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Apr 21, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 18, 2025 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Apr 18, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Apr 18, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Apr 18, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 18, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Apr 18, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Nov 5, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 10, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 10, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 21, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 6, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 2, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 2, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 2, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 12, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 12, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 12, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 30, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 30, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 30, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 29, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 29, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 29, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 29, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 28, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 1, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceuticals and therapeutic pharmaceuticals for the treatment of neurological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of immunological conditions; pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer; pharmaceuticals and therapeutic pharmaceuticals for the treatment and prevention of ophthalmic conditions
Class 042
providing a biotechnology platform, namely, providing scientific research and development, to enable drug developers to enhance structure of proteins and antibodies for use in the treatment of neurological conditions and cancer, for use in the treatment and prevention of immunological conditions and ophthalmic conditions; research and development of therapeutics for others

Classification

International Classes
005 042